BOCA RATON, Fla., June 16 /PRNewswire/ -- NovaVision today announced the appointment of Rudy Mazzocchi as its new chief executive officer. In his role, Mazzocchi is responsible for leveraging the company's novel technology to find new channels of growth to ensure that patients with impaired vision have access to NovaVision(R) Vision Restoration Therapy (VRT).
Mazzocchi has 25 years of expertise bringing new medical technologies and devices to market that address unmet clinical needs. With extensive senior management, operational and financing experience, he has served as chief executive officer and founder of many medical technology or device companies.
Most recently, he served as Managing Director of Accuitive Medical Ventures, an Atlanta-based venture capital fund that specializes in early-stage medical technology investments. Prior to that he served as chairman and interim CEO of Triton BioSystems, a company developing a nanotechnology based approach to cancer therapy and was co-founder and CEO of Image-Guided Neurologics, an early stage neurosurgical device company acquired by Medtronic in August 2005. He was also founder, president and CEO of Microvena Corporation, a public medical device company now known as "eV3". Mazzocchi holds approximately 40 medical device patents and has published numerous scientific and medical journal articles.
"I've watched NovaVision build strong momentum over the past several
years and emerge as a leading company in the area of vision restoration
therapy," said Mazzocchi. "I'm excited to build on the progress already
established. There is recently published data confirming the neuroscience
behind VRT, interest within the U.S. veteran's healthcare system for
providing VRT to American soldiers, and encouraging endorsements from
congressional delegates to support reimbursement efforts. Most important,
I'm honored to lead the team of intelligent and passionate employees who
are dedicated to improving the liv
|SOURCE NovaVision, Inc.|
Copyright©2008 PR Newswire.
All rights reserved